This is a Validated Antibody Database (VAD) review about human SLFN11, based on 4 published articles (read how Labome selects the articles), using SLFN11 antibody in all methods. It is aimed to help Labome visitors find the most suited SLFN11 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
SLFN11 synonym: SLFN8/9

Knockout validation
Santa Cruz Biotechnology
mouse monoclonal (E-4)
  • immunocytochemistry knockout validation; human; loading ...; fig s1a,b
  • western blot knockout validation; human; loading ...; fig s2b
Santa Cruz Biotechnology SLFN11 antibody (Santa Cruz Biotechnology, sc-374339) was used in immunocytochemistry knockout validation on human samples (fig s1a,b) and in western blot knockout validation on human samples (fig s2b). Oncotarget (2016) ncbi
Santa Cruz Biotechnology
mouse monoclonal
  • western blot; human; loading ...
Santa Cruz Biotechnology SLFN11 antibody (Santa Cruz Biotechnology, sc-515071) was used in western blot on human samples . Oncogene (2021) ncbi
mouse monoclonal
  • immunohistochemistry - paraffin section; human; 1:300; loading ...; fig 2
Santa Cruz Biotechnology SLFN11 antibody (Santa Cruz, sc-515071) was used in immunohistochemistry - paraffin section on human samples at 1:300 (fig 2). BMC Cancer (2020) ncbi
mouse monoclonal (E-4)
  • immunocytochemistry knockout validation; human; loading ...; fig s1a,b
  • western blot knockout validation; human; loading ...; fig s2b
Santa Cruz Biotechnology SLFN11 antibody (Santa Cruz Biotechnology, sc-374339) was used in immunocytochemistry knockout validation on human samples (fig s1a,b) and in western blot knockout validation on human samples (fig s2b). Oncotarget (2016) ncbi
mouse monoclonal (E-4)
  • immunoprecipitation; human; fig 3
  • western blot; human; fig 3
Santa Cruz Biotechnology SLFN11 antibody (Santacruz, sc-374339) was used in immunoprecipitation on human samples (fig 3) and in western blot on human samples (fig 3). Oncotarget (2016) ncbi
Articles Reviewed
  1. Fischietti M, Eckerdt F, Blyth G, Arslan A, Mati W, Oku C, et al. Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene. 2021;40:3273-3286 pubmed publisher
  2. Kagami T, Yamade M, Suzuki T, Uotani T, Tani S, Hamaya Y, et al. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer. 2020;20:1123 pubmed publisher
  3. Murai J, Feng Y, Yu G, Ru Y, Tang S, Shen Y, et al. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget. 2016;7:76534-76550 pubmed publisher
  4. Nogales V, Reinhold W, Varma S, Martinez Cardus A, Moutinho C, Moran S, et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. 2016;7:3084-97 pubmed publisher